Emcure Pharmaceuticals Ltd

The inspection conducted from 30 June 2025 to 08 July 2025 and concluded without issuance of Form 483, indicating zero observations. Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. The company's consolidated net profit jumped 64.1% to Rs 188.96 crore on 19.5% increase in net sales to Rs 2,116.25 crore in Q4 FY25 over Q4 FY24.Powered by Capital Market - Live

Emcure Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 22 May 2025, inter alia, have recommended the final dividend of Rs 3 per equity Share (i.e. 30%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Emcure Pharmaceuticals rose 64.07% to Rs 188.96 crore in the quarter ended March 2025 as against Rs 115.17 crore during the previous quarter ended March 2024. Sales rose 19.47% to Rs 2116.25 crore in the quarter ended March 2025 as against Rs 1771.36 crore during the previous quarter ended March 2024. For the full year,net profit rose 36.76% to Rs 681.33 crore in the year ended March 2025 as against Rs 498.18 crore during the previous year ended March 2024. Sales rose 18.59% to Rs 7896.00 crore in the year ended March 2025 as against Rs 6658.25 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales2116.251771.36 19 7896.006658.25 19 OPM %19.0217.58 -18.6718.47 - PBDT367.83257.61 43 1365.861049.57 30 PBT270.99167.04 62 981.73737.16 33 NP188.96115.17 64 681.33498.18 37 Powered by Capital Market - Live

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 May 2025.Powered by Capital Market - Live

The company received the Establishment Inspection Report (EIR) from the USFDA following an inspection conducted between 19 February 2025 and 25 February 2025. According to an exchange filing dated 26 February 2025, the inspection concluded with the issuance of two observations in Form 483. Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. The company's consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024. The scrip shed 0.89% to Rs 1,084.95 on the BSE. Powered by Capital Market - Live

The APA has also been inked with the subsidiaries of Manx, viz. Manx Pharma and Manx Generics. Tillomed Laboratories is a leading European pharmaceutical company focused on developing, licensing, and marketing high-quality generic medicines. Headquartered in Luton, UK, Tillomed operates across multiple European markets, ensuring access to cost-effective healthcare solutions. Under the APA, Tillomed will acquire Manx's product portfolio inclusive of relevant dossiers, marketing authorisations, intellectual property and the relevant stocks for around '19.7 million (including '4.7 million for inventory). Of the total consideration, '6.2 million will be upfront and rest as milestone payments over the next 18 months. Commenting on the development, Ajit Srimal, CEO, Tillomed said: 'Through the acquisition of Manx's established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions. The acquired assets will help diversify our portfolio and strengthen our market presence.' Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. The company's consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024. The scrip tumbled 4.90% to currently trade at Rs 982.60 on the BSE. Powered by Capital Market - Live

Tillomed Laboratories, a subsidiary of Emcure Pharmaceuticals, has entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare and its subsidiaries, Manx Pharma and Manx Generics (collectively Manx). Under the APA, Tillomed will acquire Manx's product portfolio inclusive of relevant Dossiers, Marketing Authorisations, Intellectual Property (collectively Intellectual Properties) and the relevant stocks for around ' 19.7 mn (including ' 4.7mn for inventory) of which ' 6.2 mn will be upfront and rest as milestone payments over the next 18 months. The deal marks a strategic milestone for Tillomed and will strengthen the company's product offerings, expand its market reach, and enhance its ability to meet the evolving needs of patients. Commenting on the development, Ajit Srimal, CEO Tillomed said, 'Through the acquisition of Manx's established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions. The acquired assets will help diversify our portfolio and strengthen our market presence.'Powered by Capital Market - Live

Emcutix Biopharmaceuticals, a wholly owned subsidiary of Emcure Pharmaceuticals, announced an exclusive in-licensing agreement with WiQo, an innovative Italian derma-cosmetic and medical device company specialised in scientifically validated products. The strategic partnership grants Emcutix the rights to import, promote, distribute and sell WiQo's ground breaking product PRX-PLUS in India. The collaboration is set to redefine the landscape of non-invasive skin treatments in the region. PRX-PLUS has a unique product feature with its deep-impacting formula that instantly tightens the skin, offering a non-invasive, pain-free alternative to traditional aesthetic treatments for those seeking effective results with convenience. Sathya Narayanan, CEO - Emcutix Biopharmaceuticals commented, At Emcutix Biopharmaceuticals, our vision is to bring innovative and high-quality dermatology solutions to the Indian market. Our collaboration with WiQo marks a significant step toward fulfilling this commitment, introducing PRX-PLUS, a unique and advanced skincare solution. With the strong marketing expertise of Emcutix, we are confident that PRX-PLUS will set new benchmarks in dermatological care, making cutting-edge skincare more accessible to consumers across India.Powered by Capital Market - Live

Emcure Pharmaceuticals announced its entry into the daily supplements space with the expansion of its Arth range. With a comprehensive approach to holistic well-being, Arth offers a wide range of supplements that harness the power of ancient Indian herbs like Brahmi, with the precision of modern science to address key health concerns that are often overlooked. As an initiative within its broader efforts for quality and women's health education, Emcure has partnered with acclaimed actor and women's health advocate Vidya Balan as the brand ambassador for its Arth range. A respected household name across the nation, Vidya will spark conversations around less discussed and important aspects of health, including inmate care and sleep issues, encouraging women to prioritize and take charge of their health. As a part of the association, Vidya will spotlight three key products from the Arth range: Inmate Care to soothe itchiness and dryness in inmate areas, Sleep Support Gummies for blissful and quality sleep; Brain Fog Aid to improve focus and support cognition. Powered by Capital Market - Live

Emcure Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had conducted a current Good Manufacturing Practices (cGMP) inspection of Company's API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka - Daund, Pune - 413802, Maharashtra, from 19 February 2025 to 25 February 2025. On conclusion of the inspection, the Company received two observations in Form 483.Powered by Capital Market - Live